

SAFETY DATA SHEET

Product Name: Procainamide Hydrochloride Injection

1. CHEMICAL PRODUCT AND COMPANY IDENTIFICATION

| Manufacturer Name And Address | Hospira, Inc. 275 North Field Drive Lake Forest, Illinois 60045 USA |
|----------------------------------|---|
| Emergency Telephone | CHEMTREC: North America: 800-424-9300; International 1-703-527-3887; Australia - 61-290372994; UK - 44-870-8200418 |
| Hospira, Inc., Non-Emergency | 224 212-2000 |
| Product Name | Procainamide Hydrochloride Injection |
| Synonyms | ρ-amino-N-[2-(diethylamino) ethyl] benzamide mono-hydrochloride |

2. HAZARD(S) IDENTIFICATION

| Emergency Overview | Procainamide Hydrochloride Injection is a solution containing procainamide | |
|---------------------------|--|--|
| | hydrochloride, an anti-arrhythmic agent used in the treatment of both atrial and | |
| | ventricular arrhythmias. In the workplace, this product should be considered | |
| | potentially irritating to the eyes and respiratory tract. This product also contains a sulfite and may cause an allergic reaction in persons sensitive to sulfites. Based on clinical use, possible target organs include the heart, hematopoietic system, and | |
| | | |
| | | |
| | immune system. | |

U.S. OSHA GHS Classification

| Physical Hazards | Hazard Class | Hazard Category |
|------------------|--------------------------------------|-----------------|
| | Not Classified | Not Classified |
| Health Hazards | Hazard Class | Hazard Category |
| | Eye Damage / Irritation STOT – RE | 2B 2 |

Label Element(s)

Pictogram

Signal Word



Warning

| Hazard Statement(s) Precautionary Statement(s) | Causes eye irritation May cause damage to organs through prolonged or repeated exposure |
|--|--|
| Prevention | Do not breathe vapor or spray Wash hands thoroughly after handling |
| Response | Get medical attention if you feel unwell. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists, get medical attention. |



3. COMPOSITION/INFORMATION ON INGREDIENTS

| Active Ingredient Name | Procainamide Hydrochloride |
|------------------------|--------------------------------|
| Chemical Formula | $C_{13}H_{21}N_3O \bullet HCl$ |

| Component | Approximate Percent by Weight | CAS Number | RTECS Number |
|----------------------------|-------------------------------|------------|--------------|
| Procainamide Hydrochloride | ≤50 | 614-39-1 | CV2295000 |
| | | | |

Non-hazardous ingredients include Water for Injection. Hazardous ingredients present at less than 1% may include methylparaben and sodium metabisulfite. Sodium hydroxide and/or hydrochloric acid may be use to adjust the pH.

4. FIRST AID MEASURES

| Eye Contact | Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. |
|--------------|---|
| Skin Contact | Remove from source of exposure. Flush with copious amounts of water. If irritation persists or signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. |
| Inhalation | Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. |
| Ingestion | Remove from source of exposure. If signs of toxicity occur, seek medical attention. Provide symptomatic/supportive care as necessary. |

5. FIRE FIGHTING MEASURES

| Flammability | None anticipated for this aqueous product. |
|-------------------------------------|--|
| Fire & Explosion Hazard | None anticipated for this aqueous product. |
| Extinguishing Media | As with any fire, use extinguishing media appropriate for primary cause of fire such as carbon dioxide, dry chemical extinguishing powder or foam. |
| Special Fire Fighting Procedures | No special provisions required beyond normal firefighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus. |

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and DisposalIsolate area around spill. Put on suitable protective clothing and equipment as
specified by site spill control procedures. Absorb the liquid with suitable material and
clean affected area with soap and water. Dispose of spill materials according to the
applicable federal, state, or local regulations.

7. HANDLING AND STORAGE

| Handling | No special handling required for hazard control under conditions of normal product use. |
|---------------------|---|
| Storage | No special storage required for hazard control. For product protection, follow storage recommendations noted on the product case label, the primary container label, or the product insert. |
| Special Precautions | No special precautions required for hazard control. |



8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

| | Exposure Limits | | | |
|--|-----------------|---------------|---------------|---------------|
| Component | OSHA-PEL | ACGIH-TLV | AIHA WEEL | Hospira EEL |
| Procainamide Hydrochloride | 8-hr TWA: Not | 8-hr TWA: Not | 8-hr TWA: Not | 8-hr TWA: Not |
| | Established | Established | Established | Established |
| Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit | | | | |

tes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.

AIHA WEEL: Workplace Environmental Exposure Level

EEL: Employee Exposure Limit.

TWA: 8-hour Time Weighted Average.

| Respiratory Protection | Respiratory protection is normally not needed during intended product use. However, if the generation of aerosols is likely, and engineering controls are not considered adequate to control potential airborne exposures, the use of an approved air-purifying respirator with a HEPA cartridge (N95 or equivalent) is recommended under conditions where airborne aerosol concentrations are not expected to be excessive. For uncontrolled release events, or if exposure levels are not known, provide respirators that offer a high protection factor such as a powered air purifying respirator or supplied air. A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements must be followed whenever workplace conditions require respirator use. Personnel who wear respirators should be fit tested and approved for respirator use as required. |
|------------------------|---|
| Skin Protection | If skin contact with the product formulation is likely, the use of latex or nitrile gloves is recommended. |
| Eye Protection | Eye protection is normally not required during intended product use. However, if eye contact is likely to occur, the use of chemical safety goggles (as a minimum) is recommended. |
| Engineering Controls | Engineering controls are normally not needed during the normal use of this product. |

9. PHYSICAL/CHEMICAL PROPERTIES

| Appearance/Physical State | Clear and colorless solution |
|--|------------------------------|
| Odor | NA |
| Odor Threshold | NA |
| рН | 5.0 (4.0 to 6.0) |
| Melting point/Freezing Point | NA |
| Initial Boiling Point/Boiling Point Range | NA |
| Flash Point | NA |
| Evaporation Rate | NA |
| Flammability (solid, gas) | NA |
| Upper/Lower Flammability or Explosive Limits | NA |
| Vapor Pressure | NA |
| Vapor Density (Air =1) | NA |
| Relative Density | NA |
| Solubility | NA |
| Partition Coefficient: n-octanol/water | NA |
| Auto-ignition Temperature | NA |
| Decomposition Temperature | NA |
| Viscosity | NA |



10. STABILITY AND REACTIVITY

| Reactivity | Not determined |
|-------------------------------------|---|
| Chemical Stability | Stable under standard use and storage conditions. |
| Hazardous Reactions | Not determined |
| Conditions to Avoid | Not determined |
| Incompatibilities | Not determined |
| Hazardous Decomposition Products | Not determined. During thermal decomposition, it may be possible to generate irritating vapors and/or toxic fumes of carbon oxides (COx), nitrogen oxides (NOx), and hydrogen chloride. |
| Hazardous Polymerization | Not anticipated to occur with this product. |

11. TOXICOLOGICAL INFORMATION

Acute Toxicity - Not determined for the product formulation. Information for the active ingredient is as follows:

| Ingredient(s) | Percent | Test Type | Route of Administration | Value | Units | Species |
|----------------------------|---------|-----------|----------------------------|-------------|----------------|--------------|
| Procainamide Hydrochloride | 100 | LD50 | Oral | 1509 701 | mg/kg mg/kg | Rat Mouse |
| Procainamide Hydrochloride | 100 | LD50 | Intravenous | 95 95 | mg/kg mg/kg | Rat Mouse |

LD 50: Dosage that produces 50% mortality.

| Occupational Exposure Potential | Information on the absorption of this product via inhalation or skin contact is not available. Avoid liquid aerosol generation and skin contact. |
|--|---|
| Signs and Symptoms | None known from occupational exposure. In clinical use, adverse effects may include gastrointestinal effects such as anorexia, bitter taste, abdominal pain, nausea, vomiting and diarrhea. Effects on the nervous system may include dizziness, giddiness, seizure, mental depression, confusion, and psychosis with hallucinations. Dermatologic effects may include urticaria, pruritis, and a maculopapular rash. Procainamide hydrochloride is also cardiotoxic. Toxicities may include an increase in ventricular rate when used for atrial fibrillation or flutter; tachycardia; widening of the QRS (and other conduction delays); and an increased risk of complete heart block, especially with a history of 1st or 2nd degree heart block. Elevations in liver function tests [AST (SGOT), ALT (SGPT)] and amylase may occur rarely. Persons who are sensitized to procaine or other ester-type anesthetics may develop cross-reactivity. Manifestations may be allergic dermatitis, asthma, or anaphylaxis. |
| Aspiration Hazard | None anticipated from normal handling of this product. |
| Dermal Irritation/ Corrosion | None anticipated from normal handling of this product. |
| Ocular Irritation/ Corrosion | None anticipated from normal handling of this product. However, inadvertent contact of this product with eyes may produce irritation with redness and tearing. |
| Dermal or Respiratory Sensitization | None anticipated from normal handling of this product. This product contains sodium metabisulfite which may cause allergic-type reactions in people sensitive to sulfites. |



11. TOXICOLOGICAL INFORMATION: continued

| Reproductive Effects | None anticipated from norm Studies in animals to evaluat conducted. | al handling of this product. te the affect on fertility or dev | velopment have not been |
|---|--|---|-----------------------------|
| Mutagenicity | Studies to evaluate the mutagenic potential have not been conducted. | | |
| Carcinogenicity | Long-term studies in animals to evaluate the carcinogenic potential have not been conducted. | | |
| Carcinogen Lists | IARC: Not listed | NTP: Not listed | OSHA: Not listed |
| Specific Target Organ Toxicity – Single Exposure | NA | | |
| Specific Target Organ Toxicity – Repeat Exposure | Based on clinical use, possib and immune system. | ble target organs include the h | eart, hematopoietic system, |

12. ECOLOGICAL INFORMATION

| Aquatic Toxicity | Not determined for product. |
|------------------------------|-----------------------------|
| Persistence/Biodegradability | Not determined for product. |
| Bioaccumulation | Not determined for product. |
| Mobility in Soil | Not determined for product. |
| Notes: | |

13. DISPOSAL CONSIDERATIONS

| Waste Disposal | All waste materials must be properly characterized. Further, disposal should be performed in accordance with the federal, state or local regulatory requirements. |
|------------------------------------|---|
| Container Handling and Disposal | Dispose of container and unused contents in accordance with federal, state and local regulations. |

14. TRANSPORTATION INFORMATION

| ADR/ADG/ DOT STATUS | Not regulated |
|----------------------|---------------|
| Proper Shipping Name | NA |
| Hazard Class | NA |
| UN Number | NA |
| Packing Group | NA |
| Reportable Quantity | NA |
| ICAO/IATA STATUS | Not regulated |
| Proper Shipping Name | NA |
| Hazard Class | NA |
| UN Number | NA |
| Packing Group | NA |
| Reportable Quantity | NA |
| IMDG STATUS | Not regulated |
| Proper Shipping Name | NA |
| Hazard Class | NA |
| UN Number | NA |
| Packing Group | NA |
| Reportable Quantity | NA |

Notes: DOT - US Department of Transportation Regulations



15. REGULATORY INFORMATION

| US TSCA Status | Exempt |
|---------------------|------------|
| US CERCLA Status | Not listed |
| US SARA 302 Status | Not listed |
| US SARA 313 Status | Not listed |
| US RCRA Status | Not listed |
| US PROP 65 (Calif.) | Not listed |

Notes: TSCA, Toxic Substance Control Act; CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act; SARA, Superfund Amendments and Reauthorization Act; RCRA, US EPA, Resource Conservation and Recovery Act; Prop 65, California Proposition 65

| GHS/CLP Classification* | *In the EU, classification under GHS/CLP does not apply to certain substances and mixtures, such as medicinal products as defined in Directive 2001/83/EC, which are in the finished state, intended for the final user. | | | |
|---|--|------------------------|-------------------------|------------------|
| Hazard Class | Hazard Category | Pictogram | Signal Word | Hazard Statement |
| NA | NA | NA | NA | NA |
| Prevention | Do not breathe vapor or spray Wash hands thoroughly after handling | | | |
| Response | Get medical attention if you feel unwell. | | | |
| EU Classification* | IF IN EYES: Rinse ca if present and easy to a attention. *Medicinal products a | do. Continue rinsi | ng. If eye irritation p | |
| | Preparations Directive | · · | | C |
| Classification(s) Symbol Indication of Danger Risk Phrases Safety Phrases | NA NA NA S23: Do not breathe va S24: Avoid contact wi S25: Avoid contact wi S37/39 Wear suitable | th the skin th eyes | e protection. | |



16. OTHER INFORMATION

Notes:

| ACGIH TLV | American Conference of Governmental Industrial Hygienists – Threshold Limit Value |
|-------------------|---|
| CAS | Chemical Abstracts Service Number |
| CERCLA | US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act |
| DOT | US Department of Transportation Regulations |
| EEL | Employee Exposure Limit |
| IATA | International Air Transport Association |
| LD_{50} | Dosage producing 50% mortality |
| NA | Not applicable/Not available |
| NE | Not established |
| NIOSH | National Institute for Occupational Safety and Health |
| OSHA PEL | US Occupational Safety and Health Administration – Permissible Exposure Limit |
| Prop 65 | California Proposition 65 |
| RCRA | US EPA, Resource Conservation and Recovery Act |
| RTECS | Registry of Toxic Effects of Chemical Substances |
| SARA | Superfund Amendments and Reauthorization Act |
| STEL | 15-minute Short Term Exposure Limit |
| STOT - SE | Specific Target Organ Toxicity – Single Exposure |
| STOT - RE | Specific Target Organ Toxicity – Repeated Exposure |
| TSCA | Toxic Substance Control Act |
| TWA | 8-hour Time Weighted Average |
| MSDS Coordinator: | Hospira GEHS |
| Date Prepared: | October 19, 2012 |
| Date Revised: | June 02, 2014 |

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.